Amati AIM VCT (AMAT) Competitors

Amati AIM VCT (LON:AMAT) and Alliance Pharma (LON:APH) are both small-cap financial services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, profitability, dividends, valuation, earnings, community ranking, risk and analyst recommendations.

Is AMAT or APH a better dividend stock?

Amati AIM VCT pays an annual dividend of GBX 5 per share and has a dividend yield of 8.8%. Alliance Pharma pays an annual dividend of GBX 2 per share and has a dividend yield of 3.1%. Amati AIM VCT pays out -68.7% of its earnings in the form of a dividend. Alliance Pharma pays out -32.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Amati AIM VCT is clearly the better dividend stock, given its higher yield and lower payout ratio.

Does the MarketBeat Community favor AMAT or APH?

Alliance Pharma received 186 more outperform votes than Amati AIM VCT when rated by MarketBeat users. However, 70.83% of users gave Amati AIM VCT an outperform vote while only 61.89% of users gave Alliance Pharma an outperform vote.

Company	Underperform	Outperform
Amati AIM VCT	Outperform Votes 17 70.83%	Underperform Votes 7 29.17%
Alliance Pharma	Outperform Votes 203 61.89%	Underperform Votes 125 38.11%

Does the media prefer AMAT or APH?

In the previous week, Amati AIM VCT's average media sentiment score of 0.00 equaled Alliance Pharma'saverage media sentiment score.

Company	Overall Sentiment
Amati AIM VCT	Neutral
Alliance Pharma	Neutral

Which has stronger earnings & valuation, AMAT or APH?

Amati AIM VCT has higher earnings, but lower revenue than Alliance Pharma. Alliance Pharma is trading at a lower price-to-earnings ratio than Amati AIM VCT, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amati AIM VCT	-£5.65M	-14.69	-£10.76M	-£7.28	-7.77
Alliance Pharma	£183.50M	1.90	-£33.65M	-£6.20	-10.40

Do analysts recommend AMAT or APH?

Alliance Pharma has a consensus target price of GBX 6,250, suggesting a potential upside of 9,589.92%. Given Alliance Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Alliance Pharma is more favorable than Amati AIM VCT.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amati AIM VCT	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alliance Pharma	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Do insiders and institutionals believe in AMAT or APH?

66.3% of Alliance Pharma shares are owned by institutional investors. 0.5% of Amati AIM VCT shares are owned by company insiders. Comparatively, 12.0% of Alliance Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Is AMAT or APH more profitable?

Amati AIM VCT has a net margin of 190.46% compared to Alliance Pharma's net margin of -18.34%. Amati AIM VCT's return on equity of -14.97% beat Alliance Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amati AIM VCT	190.46%	-14.97%	-4.56%
Alliance Pharma	-18.34%	-15.24%	5.98%

Which has more volatility and risk, AMAT or APH?

Amati AIM VCT has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Alliance Pharma has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Summary

Alliance Pharma beats Amati AIM VCT on 10 of the 17 factors compared between the two stocks.